For example, self-assembled nano-PROTACs (DdLD NPs) can decrease glycolysis in colorectal cancer, downregulate PD-L1 expression, and concurrently prompt immunogenic cell death through chemotherapy, initiating systemic anti-tumor immunity and significantly averting the advancement of both primary and metastatic colorectal cancer while minimizing notable systemic side effects, thus offering a novel strategy for merging chemotherapy with immunotherapy [49]. The gene discussed is CD274; the disease is neoplasm.